XML 262 R216.htm IDEA: XBRL DOCUMENT v3.24.0.1
Segment information - Schedule of Reconciliation Between Business Operating Income for the Segments and Income Before Tax and Investments Accounted for Using the Equity Method (Details)
€ in Millions, $ in Millions
 1 Months Ended 12 Months Ended
Nov. 30, 2022
EUR (€)
Nov. 30, 2022
USD ($)
Dec. 31, 2023
EUR (€)
Dec. 31, 2022
EUR (€)
Dec. 31, 2022
USD ($)
Dec. 31, 2021
EUR (€)
Disclosure of operating segments [line items]            
Share of profit/(loss) from investments accounted for using the equity method     € (115) € 68   € 39
Net income attributable to non-controlling interests     36 113   56
Fair value remeasurement of contingent consideration     (93) 27   (4)
Restructuring costs and similar items     (1,490) (1,336)   (820)
Other gains and losses, and litigation     (38) (370)   (5)
Operating income     7,875 10,656   8,126
Financial expenses     (1,313) (440)   (368)
Financial income     591 206   40
Income before tax and investments accounted for using the equity method     7,153 10,422   7,798
Immuno-oncology collaboration agreement | Regeneron Pharmaceuticals, INC            
Disclosure of operating segments [line items]            
Upfront payments for projects under collaboration agreements | $         $ 900  
Regular milestone payments for projects under collaboration agreements € 96 $ 100     $ 100  
Other intangible assets            
Disclosure of operating segments [line items]            
Impairment of other intangible assets, net of reversals (excluding software)     932 (454)   192
Other intangible assets | NK Cell and ProXTen technology platforms            
Disclosure of operating segments [line items]            
Impairment of other intangible assets, net of reversals (excluding software)     833      
Other intangible assets | SAR444245            
Disclosure of operating segments [line items]            
Impairment of other intangible assets, net of reversals (excluding software)       1,586    
ELOCTATE            
Disclosure of operating segments [line items]            
Reversal amount       2,154    
Operating segments            
Disclosure of operating segments [line items]            
Business operating income     12,670 13,040   10,714
Material reconciling items            
Disclosure of operating segments [line items]            
Share of profit/(loss) from investments accounted for using the equity method     (122) (88)   (39)
Net income attributable to non-controlling interests     36 33   56
Amortization and impairment of intangible assets     (3,068) (1,599)   (1,772)
Fair value remeasurement of contingent consideration     (93) 27   (4)
Expenses arising from the impact of acquisitions on inventories     (20) (3)   (4)
Restructuring costs and similar items     (1,490) (1,336)   (820)
Other gains and losses, and litigation     (38) (370)   (5)
Income from out-licensing     € 0 € 952   € 0